Literature DB >> 15254419

The PIK3CA gene is mutated with high frequency in human breast cancers.

Kurtis E Bachman1, Pedram Argani, Yardena Samuels, Natalie Silliman, Janine Ptak, Steve Szabo, Hiroyuki Konishi, Bedri Karakas, Brian G Blair, Clarence Lin, Brock A Peters, Victor E Velculescu, Ben Ho Park.   

Abstract

The phosphatidylinositol 3-kinases (PI3Ks) are known regulators of cellular growth and proliferation. It has recently been reported that somatic mutations within the PI3K subunit p110alpha (PIK3CA) are present in human colorectal and other cancers. Here we show that thirteen of fifty-three breast cancers (25%) contain somatic mutations in PIK3CA, with the majority of mutations located in the kinase domain. These results demonstrate that PIK3CA is the most mutated oncogene in breast cancer and support a role for PIK3CA in epithelial carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15254419     DOI: 10.4161/cbt.3.8.994

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  248 in total

1.  A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations.

Authors:  Brian G Blair; Xinyan Wu; Muhammad Saddiq Zahari; Morassa Mohseni; Justin Cidado; Hong Yuen Wong; Julia A Beaver; Rory L Cochran; Daniel J Zabransky; Sarah Croessmann; David Chu; Patricia Valda Toro; Karen Cravero; Akhilesh Pandey; Ben Ho Park
Journal:  Proteomics       Date:  2014-12-28       Impact factor: 3.984

Review 2.  Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications.

Authors:  Brent N Rexer; Carlos L Arteaga
Journal:  Crit Rev Oncog       Date:  2012

Review 3.  Molecular prescreening to select patient population in early clinical trials.

Authors:  Jordi Rodón; Cristina Saura; Rodrigo Dienstmann; Ana Vivancos; Santiago Ramón y Cajal; José Baselga; Josep Tabernero
Journal:  Nat Rev Clin Oncol       Date:  2012-04-03       Impact factor: 66.675

4.  RNAi knockdown of PIK3CA preferentially inhibits invasion of mutant PIK3CA cells.

Authors:  Xin-Ke Zhou; Sheng-Song Tang; Gao Yi; Min Hou; Jin-Hui Chen; Bo Yang; Ji-Fang Liu; Zhi-Min He
Journal:  World J Gastroenterol       Date:  2011-08-28       Impact factor: 5.742

5.  Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo.

Authors:  Haijun Zhang; Di Chen; Jonathan Ringler; Wei Chen; Qiuzhi Cindy Cui; Stephen P Ethier; Q Ping Dou; Guojun Wu
Journal:  Cancer Res       Date:  2010-04-27       Impact factor: 12.701

Review 6.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Todd Waldman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

7.  Sequence analysis of mutations and translocations across breast cancer subtypes.

Authors:  Shantanu Banerji; Kristian Cibulskis; Claudia Rangel-Escareno; Kristin K Brown; Scott L Carter; Abbie M Frederick; Michael S Lawrence; Andrey Y Sivachenko; Carrie Sougnez; Lihua Zou; Maria L Cortes; Juan C Fernandez-Lopez; Shouyong Peng; Kristin G Ardlie; Daniel Auclair; Veronica Bautista-Piña; Fujiko Duke; Joshua Francis; Joonil Jung; Antonio Maffuz-Aziz; Robert C Onofrio; Melissa Parkin; Nam H Pho; Valeria Quintanar-Jurado; Alex H Ramos; Rosa Rebollar-Vega; Sergio Rodriguez-Cuevas; Sandra L Romero-Cordoba; Steven E Schumacher; Nicolas Stransky; Kristin M Thompson; Laura Uribe-Figueroa; Jose Baselga; Rameen Beroukhim; Kornelia Polyak; Dennis C Sgroi; Andrea L Richardson; Gerardo Jimenez-Sanchez; Eric S Lander; Stacey B Gabriel; Levi A Garraway; Todd R Golub; Jorge Melendez-Zajgla; Alex Toker; Gad Getz; Alfredo Hidalgo-Miranda; Matthew Meyerson
Journal:  Nature       Date:  2012-06-20       Impact factor: 49.962

Review 8.  The PIK3CA gene as a mutated target for cancer therapy.

Authors:  John P Gustin; David P Cosgrove; Ben Ho Park
Journal:  Curr Cancer Drug Targets       Date:  2008-12       Impact factor: 3.428

9.  Fine-tuning AKT kinase activity through direct lysine methylation.

Authors:  Jianping Guo; Wenyi Wei
Journal:  Cell Cycle       Date:  2019-05-03       Impact factor: 4.534

10.  Fish oil targets PTEN to regulate NFkappaB for downregulation of anti-apoptotic genes in breast tumor growth.

Authors:  Triparna Ghosh-Choudhury; Chandi C Mandal; Kathleen Woodruff; Patricia St Clair; Gabriel Fernandes; Goutam G Choudhury; Nandini Ghosh-Choudhury
Journal:  Breast Cancer Res Treat       Date:  2008-10-26       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.